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Abstract
Optimal immune activation of naı¨ve CD8 T cells requires signal 1 mediated by the T cell receptor, signal 2 mediated by co-
stimulation and signal 3 provided by pro-inflammatory cytokines. However, the potential for signal 3 cytokines to rescue
anti-viral responses in functionally exhausted T cells has not been defined. We investigated the effect of using third signal
cytokines IL-12 or IFN-a to rescue the exhausted CD8 T cell response characteristic of patients persistently infected with
hepatitis B virus (HBV). We found that IL-12, but not IFN-a, potently augmented the capacity of HBV-specific CD8 T cells to
produce effector cytokines upon stimulation by cognate antigen. Functional recovery mediated by IL-12 was accompanied
by down-modulation of the hallmark inhibitory receptor PD-1 and an increase in the transcription factor T-bet. PD-1 down-
regulation was observed in HBV but not CMV-specific T cells, in line with our finding that the highly functional CMV
response was not further enhanced by IL-12. IL-12 enhanced a number of characteristics of HBV-specific T cells important
for viral control: cytotoxicity, polyfunctionality and multispecificity. Furthermore, IL-12 significantly decreased the pro-
apoptotic molecule Bim, which is capable of mediating premature attrition of HBV-specific CD8 T cells. Combining IL-12
with blockade of the PD-1 pathway further increased CD8 functionality in the majority of patients. These data provide new
insights into the distinct signalling requirements of exhausted T cells and the potential to recover responses optimised to
control persistent viral infections.
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Introduction
Successful T cell activation requires a T cell receptor (TCR)-
mediated signal accompanied by a co-stimulatory signal through
receptors such as CD28. In addition to these two signals, it is
increasingly recognised that a third signal provided by the pro-
inflammatory cytokines IL-12 and/or IFN-a can contribute to
CD8 T cell activation [1]. Provision of a third signal during
priming of naı¨ve T cells prevents tolerance induction and cell
death and is vitally important in shaping the memory response [1].
Although initially described to shape the lineage commitment of
CD4 T cells and thereby indirectly influence CD8 T cells, it has
become clear that IL-12 and IFN-acan act directly on CD8 T
cells, stimulating their activation [2,3,4]. In addition to their role in
T cell priming, third signal cytokines are required for the
reactivation of protective memory responses during secondary
infections [5]. Whether a third signal cytokine can help to
reactivate T cells exhibiting the characteristics of exhaustion in
persistent viral infection has not been explored and is the focus of
this study.
T cell exhaustion is characterised by a progressive, hierarchical
loss of effector function, culminating in T cell deletion. Critical
factors driving T cell exhaustion in the setting of persistent viral
infection include high antigen load and an excess of co-inhibitory
signals. Blocking co-inhibitory signals such as programmed death-
1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) and/or
enhancing co-stimulation through receptors such as 4-1BB can
restore some functional responses in persistent viral infection
[6,7,8]. Blockade of inhibitory cytokines such as IL-10 and TGF-b
has also been found to provide some reversal of T cell exhaustion
[9,10]. We postulated that the addition of a third signal cytokine
would further augment the functional recovery of exhausted T
cells.
We tested this postulate using T cells isolated from patients with
chronic Hepatitis B virus infection (CHB). T cells in this setting are
prone to Bcl-2 interacting mediator (Bim)-mediated apoptosis and
are strikingly depleted in patients with chronic compared to
resolved infection [11]. The remaining HBV-specific T cells
exhibit the characteristics of exhaustion, with up-regulation of
inhibitory molecules and down-regulation of effector function
[12,13]. Previous studies have demonstrated the potential to
reconstitute functional HBV-specific T cells by blocking PD-1,
CTLA-4 or both [12,13]. However, there was incomplete rescue
of HBV T cell specificities and not all patients responded to these
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strategies to enhance signal 2. Here we explored the potential for
signal 3 cytokines to recover effector functions of CD8 T cells
directed against chronic viral infections. We found that upon
IL-12 stimulation, HBV-specific T cells down-regulated PD-1
expression and showed significantly increased antiviral potential
upon recognition of cognate antigen. However, control T cell
responses in the same patients, directed against CMV and not
exhibiting features of exhaustion, did not show changes in PD-1
expression or increased anti-viral responses above those
triggered by cognate antigen alone. Our data therefore suggest
that IL-12 is particularly beneficial for enhancing TCR-
mediated signalling in T cell responses that are exhausted.
Furthermore, IL-12 can significantly augment the effects of co-
inhibitory blockade.
Results
Differential effect of third signal cytokines on HBV-
specific CD8 T cells
CD8 T cells able to produce IFN-c upon recognition of HBV
epitopes are markedly reduced in patients with persistent infection
[14,15]. We investigated the capacity of the third signal cytokines
IL-12 and IFN-a to rescue functional HBV-specific CD8 T cell
responses. PBMC from chronic hepatitis B (CHB) patients were
stimulated with HBV peptides (a panel representing well-defined
HLA-A2-restricted epitopes or overlapping peptides (OLP) span-
ning the entire core protein), and cultured in IL-2-enriched
medium supplemented with either IL-12 or IFN-a. The addition
of IFN-a did not recover any IFN-c-producing HBV-specific CD8
T cells (Figure 1a). By contrast, CD8 T cells cultured in the
presence of IL-12 showed a marked increase in IFN-c production
above those stimulated with peptide with or without IFN-a
(Figure 1a). Global CD8 T cell yield in the presence of IFN-a was
also significantly reduced, as assessed by numbers of live CD8 T
cells detected at the end of culture after dead cell exclusion,
whereas their numbers were relatively preserved with IL-12
(Figure 1b). These results suggested that IL-12 is a more potent
third signal than IFN-a in stimulating CD8 effector function and
preserving T cell numbers in the setting of CHB.
We next investigated whether exogenous IL-12 was able to
increase not only the frequency of IFN-c+ T cells but also the
amount of IFN-c produced on a per cell basis. We observed that
IL-12 was able to consistently increase the amount of IFN-c
produced per cell, indicated by an increase in IFN-c mean
fluorescence intensity (MFI) in CD8 T cells responding to HBV
peptide stimulation (Figure 2a).
Since IL-12 in combination with IL-18 has been reported to
trigger some bystander production of IFN-c by murine CD8 T
cells [2,4], we extended our examination of the effect of IL-12 to a
larger cohort of 73 patients with CHB, comparing the addition of
IL-12 with or without HBV peptides (Figure 2b). The combination
of HBV peptides with IL-12 (providing signal 1 and 3) stimulated
significantly more IFN-c+ cells than either HBV peptide or IL-12
alone (Figure 2b). This finding was true whether optimal HLA-A2-
restricted or overlapping peptides spanning HBV core (to
stimulate T cells derived from HLA-A2 negative patients) were
used (Figure 2c). To validate that the boosting effect of IL-12 was
not only effective after short-term culture of CD8 T cells, PBMC
were stimulated with HBV-derived peptides in the presence or
absence of IL-12 overnight. Responses to HBV-derived peptides
alone were, as expected in CHB, very weak, but even at this early
time point IFN-c responses were enhanced by IL-12 (Figure 2d).
This finding suggested that virus-specific T cells present in
peripheral blood could recover some functionality. Of note, IL-
12 did induce an increase in IFN-c+ CD8 T cells in overnight and
short-term cultures in the absence of peptide, suggesting it may
also activate responses in a non-antigen-dependent manner
(Figure 2b, c and d). CD4 T cells also showed increased IFN-c
production when stimulated with IL-12. This augmentation was,
however, non-specific since stimulation with overlapping peptides
spanning HBV core had no influence on the magnitude of the
response (Figure 2e).
To probe the potential of IL-12 to boost functional HBV-
specific CD8 T cell responses within the liver, we isolated
intrahepatic lymphocytes (IHL) from six patients with CHB. Four
out of six patients showed an increased HBV response upon IL-12
treatment of liver infiltrating lymphocytes after overnight stimu-
lation; in all cases the effect of IL-12 was more pronounced on
IHL than on PBMC from the same patients (Figure S1).
In order to investigate the utility of IL-12 to rescue HBV-
specific CD8 T cells in an immunotherapeutic setting, we
compared its efficacy in vitro using samples from patients
undergoing antiviral therapy (Table SI). PBMC derived from four
patients with CHB were tested for responsiveness to IL-12 before
and during potent antiviral therapy. In all four cases CD8 T cells
remained responsive to IL-12 to a greater or lesser extent during
treatment (Figure S2). In one case anti-HBV responses could only
be detected on treatment and were greatly augmented by IL-12.
The extent of CD8 T cell functional augmentation achieved
with IL-12 stimulation did not correlate with viral load, alanine
transaminase (ALT) or hepatitis B eAg (HBeAg) status in our large
patient cohort (data not shown). However recovery of responses
upon IL-12 stimulation did correlate with circulating levels of
hepatitis B surface antigen (HBsAg); patients with an HBsAg titre
less than 6000 IU/ml showed variable IL-12 responsiveness, with
the potential for large increases in functional HBV-specific CD8 T
cells. By contrast, none of the patients in whom HBsAg was
greater than 6000 IU/ml showed a substantial augmentation upon
IL-12 stimulation (Figure 2f).
IL-12 boosts antigen responsiveness by HBV-specific but
not CMV-specific CD8 T cells
To further investigate the antigen specificity of IFN-c boosting
by IL-12, we identified virus-specific T cells with MHC-peptide
multimers and assessed the capacity of these populations to
produce IFN-c upon peptide stimulation. PBMC from patients
Author Summary
Persistent viral infections continue to cause major mor-
bidity and mortality; chronic hepatitis B virus infection
alone accounts for more than a million deaths annually.
Such infections are characterised by a failure of viral
control perpetuated by exhaustion of the T cell response.
Here we show that the cytokine IL-12 can act as a potent
‘‘third signal’’ to rescue antiviral function in exhausted T
cells. IL-12 has previously been shown to enhance naı¨ve T
cell responses but this is the first demonstration of its
capacity to boost the disabled antiviral response in a
persistent viral infection. IL-12 was able to down-regulate
PD-1, a key inhibitory receptor driving T cell exhaustion,
resulting in the recovery of hepatitis B virus-specific
responses able to mediate multiple antiviral functions.
Control responses in the same patients directed against
the well-controlled cytomegalovirus did not require IL-12
to function efficiently. Our findings therefore elucidate a
role for IL-12 in re-programming functionally exhausted T
cells in persistent viral infections.
IL-12 Rescues Exhausted T Cells
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with CHB were cultured for ten days in the presence of peptides
representing well-described HLA-A2-restricted HBV epitopes or
for comparison, an immunodominant HLA-A2-restricted CMV
epitope, and stained with HLA-A2-peptide dextramers of matched
specificity. To prevent false positive events from contaminating the
low frequency of genuine HBV/multimer-staining CD8 T cells,
we excluded dead cells and B cells using a fixable live/dead dye
and CD19 respectively (Figure S3). The small populations
remaining after this stringent gating strategy able to bind the
combined panel of HLA-A2/HBV peptide dextramers were
barely able to produce any IFN-c (Figure 3a). This was in contrast
to CD8 T cells specific for CMV, which showed robust IFN-c
production when stimulated with their cognate peptide (Figure 3a).
These experiments were repeated with or without the addition
of IL-12 at the start of the ten day culture. IL-12 did not have any
consistent effect on the number of dextramer positive cells
expanding in culture (Figure S4). However, IL-12 was able to
recover IFN-c production by HLA-A2/HBV peptide dextramer-
binding CD8 T cells in the majority of patients tested (regardless of
viral load, ALT or eAg status), in some cases restoring it to
proportions analogous to control CMV responses (Figure 3b,c). In
contrast to the effect on global T cells, IL-12 alone in the absence
of peptide could only marginally stimulate HBV multimer-binding
CD8 T cells (Figure 3c). These results indicate that HBV-specific,
exhausted T cells benefit from receiving a signal 3 (IL-12) but also
need stimulation via the TCR (signal 1) to recover functionality.
The stimulatory effect of IL-12 could be seen as early as the first
day of culture. To assess whether IL-12 could induce IFN-c
production by HBV-specific T cells directed against the epitopes
derived from the different HBV proteins, PBMC from HLA-A2
positive patients were stimulated with either core, envelope or
polymerase derived peptides in the presence or absence of IL-12.
Staining with the matched HLA-A2/HBV peptide dextramers
showed that IL-12 had the capacity to increase IFN-c production
by T cells directed against core, envelope and polymerase proteins
(Figure S5).
To investigate whether boosting of responses by IL-12 was a
feature of all HBV-specific responses regardless of the disease
setting, we stimulated CD8T cells from patients who had previously
resolved HBV infection with HBV-derived peptides in the presence
or absence of IL-12. The vigorous IFN-c response triggered by
peptide recognition alone could not be significantly enhanced in the
CD8 T cells from resolved patients, suggesting that the requirement
for additional stimulation by IL-12 is specific to the exhausted CD8
T cell responses in chronic infection (Figure S6). To further examine
whether the dependence of HBV-specific T cells on signal 3 was a
feature of their exhausted phenotype or was shared by T cells of
other specificities circulating in patients with CHB, we assessed the
effect of IL-12 on CMV-reactive T cells. IL-12 had no influence on
IFN-c production by CMV dextramer-binding T cells, resulting in
no increase above that seen with peptide stimulation alone
(Figure 3d). The lack of IL-12-induced augmentation of IFN-c
production by CMV-specific CD8 T cells was seen regardless of
whether the donors were healthy or had CHB (Figure 3e). Of note,
IL-12 alone could trigger IFN-c production by approximately 10%
of CMV-specific T cells in the absence of cognate peptide (Figure 3e,
right panel), suggesting that these prevalent responses may
contribute to the bystander effect we had observed with IL-12.
Figure 1. IL-12 but not IFN-a increases IFN-c production by HBV-specific CD8 T cells. a) PBMC from CHB patients were stimulated with HBV
derived peptides and cultured for 10 days in the presence or absence of IL-12 or IFN-a. Cells were then restimulated with HBV-derived peptides
overnight and IFN-c production from CD8+ T cells was quantified by intracellular FACS. Representative FACS plots and summary data are shown. b)
Cumulative data showing the fold change in cell yield compared to control unstimulated PBMCs cultured in the absence of HBV peptide. Numbers of
CD8 T cells were measured by using a live/dead staining kit to exclude dead cells after 10 days culture.
doi:10.1371/journal.ppat.1003208.g001
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Pleiotropic effect of IL-12 in restoring functional HBV-
specific CD8 T cells
CD8 T cells that are able to simultaneously exert a number of
different effector functions have been shown to be important in
overcoming persistent viral infections [16,17]. Very few of the
HBV-specific CD8 T cells detectable using IFN-c and TNF-a as a
readout after peptide stimulation were able to produce both
cytokines (Figure 4a). The addition of IL-12 was able to
significantly boost both the frequency (data not shown) and the
proportion of IFN-c/TNF-a double-positive CD8 T cell responses
(Figure 4a). Although IFN-c and TNF-a can potently control
HBV replication in a non-cytolytic manner, CD8 cytotoxicity is
likely to be required for the final clearance of replicative
intermediates [18]. T cells stimulated with IL-12 also showed an
increase in their capacity for cytotoxic degranulation, as evidenced
by an upregulation in surface expression of CD107a, which was
independent of peptide stimulation (Figure 4b). In accordance with
previously published work [19] and in line with the hierarchical
loss of effector function characteristic of exhaustion [20], IL-2
production by HBV-specific T cells was rarely detected and was
not recovered upon stimulation with IL-12 (Figure 4c). IL-12 was,
however, able to induce the survival of a population of HBV-
specific CD8 T cells exhibiting reduced expression of the pro-
apoptotic molecule Bim (Figure 4d), previously implicated in their
premature attrition [11].
IL-12 stimulation leads to down-regulation of the co-
inhibitory molecule PD-1
The co-inhibitory molecule PD-1 is a marker of exhaustion that
is highly expressed on virus-specific T cells in persistent viral
infections, including CHB [14,21] (Figure 5a,b). We found that the
upregulation in frequency and intensity of PD-1 expressing HBV-
specific CD8 T cells seen upon culture was significantly reduced in
the presence of IL-12 (Figure 5a,b). In contrast, CMV-specific T
cells, which are not considered to be functionally exhausted [22],
expressed considerably lower levels of PD-1 compared to HBV-
specific T cells in the same CHB patients. CMV-specific T cells
did not show a decrease in PD-1 expression upon IL-12
stimulation (Figure 5 a,b).
Strong increases in IFN-c production upon stimulation with
HBV-derived peptide in combination with IL-12 could only be
observed in those samples with decreased expression of PD-1
(compared to the group treated with peptide alone, Figure 5c and
individual responses, Figure S7).
In a mouse model of chronic LCMV infection, the transcription
factor T-bet has recently been shown to counteract CD8 T cell
exhaustion by down-regulating PD-1 and sustaining effector
cytokine production in virus-specific cells [23]. In accordance
with this, we found reduced expression of PD-1 on HBV-specific
CD8 T cells with high levels of T-bet (Figure 5d). As T-bet
transactivates IFN-c gene expression we sought to evaluate
whether it played a role in the increased functionality of IL-12
treated cells. When the IFN-c+ CD8 T cell population was
subdivided into high and low IFN-c producers, those responding
to IL-12 with the most efficient IFN-c production were found to
express uniformly high levels of T-bet (Figure 5e). Furthermore, all
the IFN-c/TNF-a double-producing CD8 T cells obtained after
culture in the presence of HBV peptides and IL-12 were T-bet
positive, whilst the single producers showed lower frequencies of T
bet expression (Figure 5f).
IL-12 enhances the capacity of co-inhibitory blockade to
rescue exhausted T cells
Although IL-12 could significantly decrease PD-1 expression on
HBV-specific T cells, levels were still not as low as on control
CMV-specific T cell responses (Figure 5a,b). We therefore
postulated that blocking residual PD-1 signalling whilst stimulating
with IL-12 would synergistically recover exhausted T cells.
Blockade of inhibitory signalling via PD-L1/2 without IL-12
increased T cell IFN-c production in 11 of the 28 patients tested
(Figure 6a,b), in line with previous studies showing that not all
patients show a functional recovery with this strategy [13].
However, when PD-L1/2 blockade was combined with IL-12
stimulation, IFN-c production was enhanced in all but one patient,
irrespective of ALT, eAg status or viral load (including all five
patients with viral load above 1 million IU/ml, Figure 6a,b).
Furthermore, the combination had a beneficial effect over IL-12
alone in 14 out of 28 patients (Figure 6a,b). To validate that this
additional effect was not due to bystander activation, but to the
recovery of functional HBV-specific T cells, we assessed IFN-c
production by HBV dextramer+ CD8 T cells after stimulation
with IL-12 and PD-L1/2 blockade. The results confirmed that
HBV-specific T cell function was significantly enhanced by the
addition of IL-12 to PD-L1 blockade, with six out of nine patients
showing optimal recovery when treated with the combination of
PD-L1/2 blockade and IL-12 (Figure 6c).
Discussion
Multiple mechanisms combine to drive T cell exhaustion and
limit effective antiviral responses in the setting of chronic viral
infections. The combination of a persistently high viral load and
the tolerogenic liver environment promotes many such mecha-
nisms, with intrahepatic priming imposing a Bimhigh pro-apoptotic
phenotype on T cells, whilst the excess of co-inhibitory signals
from liver resident cells impairs their effector function [24]. We
found that the signal 3 cytokine IL-12 can overcome these defects
to recover polyfunctional, multispecific CD8 T cell responses with
reduced levels of Bim and PD-1. Exhausted T cell responses
directed against HBV in patients with persistent infection
benefitted from the addition of IL-12 to signal 1 whereas they
did not respond to IL-12 alone. Conversely, T cells that had not
Figure 2. IL-12 in combination with T cell receptor stimulation increases IFN-c production irrespective of HLA-type but dependent
on HBsAg levels. a) The effect of IL-12 on IFN-c production on a per cell basis was measured by changes in IFN-c MFI after restimulation of PBMC
cultured for 10 days with HBV peptides in the presence or absence of IL-12. Representative FACS plot gated on CD8 T cells, IFN-c-overlay histogram
and summary data. b) Representative FACS plot and summary data of CD8 T cell IFN-c production after 10 days culture with HBV peptides, HBV
peptides with IL-12, or IL-12 in the absence of peptide, background IFN-c produced in corresponding unstimulated control samples has been
subtracted. c) Data from Figure 2b were split into responses produced by HLA-A2 positive (stimulated with HLA-A2 restricted immunodominant
peptides) and HLA-A2 negative (stimulated with core OLP) samples. d) PBMC were stimulated over night with HBV-derived peptides in the presence
or absence of IL-12, in the presence of Brefeldin A. IFN-c production was assessed by intracellular staining. e) PBMC from HLA-A2 negative patients
were stimulated in the presence or absence of core OLP and/or IL-12 and cultured for 10 days, before peptide restimulation. T cells were gated on the
CD3 positive CD8 negative fraction (denoted as CD4+) and IFN-c production assessed by intracellular staining. f) Patients were stratified according to
serum HBsAg levels (available for n= 22, divided according to a threshold of 6000 IU/ml) and the increase in IFN-c response frequency upon HBV+ IL-
12 stimulation above stimulation by HBV-peptide alone is shown (%IFN-c (HBV+IL-12) - % IFN-c (HBV)).
doi:10.1371/journal.ppat.1003208.g002
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been driven to a state of exhaustion (HBV-specific T cells in
patients with resolved infection or CMV responses in patients with
persistent HBV infection) were more responsive to the bystander
effects of IL-12 but did not require it to enhance signal 1. Our data
therefore provide new insights into the distinct signalling
requirements of exhausted T cells and reveal a strategy to recover
T cell responses with the potential to control persistent viral
infections.
Stimulation with another signal 3 cytokine, IFN-a, did not
recover any IFN-c-producing HBV-specific CD8 T cells in vitro, in
line with the failure of therapeutic IFN-a to recover functional
responses against HBV in vivo [25]. By contrast, IL-12 has the
potential to reduce viraemia through the induction of IFN-c-
producing T cells in the HBV transgenic mouse model [26], in
woodchuck hepatitis virus infection [27] and in patients with CHB
[28,29]. Exploring the mechanism of action of IL-12 on exhausted
HBV-specific CD8 T cells, we found that it potently increased
IFN-c and TNF-a production and enhanced their capacity to
produce both cytokines simultaneously. IL-12 also boosted CD8
cytotoxicity but could not consistently increase IL-2 or T cell
expansion. This is consistent with the observation that exposure of
naı¨ve human T cells to IL-12 in vitro preferentially leads to
formation of CD8 effector memory cells that efficiently produce
effector cytokines but are poor at proliferative expansion, whereas
IFN-a induces CD8 central memory cells [30].
The development of end stage effectors during LCMV infection
is instructed by pro-inflammatory signals from IL-12, which acts
via induction of the transcription factor T-bet [31]. In CD8 T
cells, T-bet is expressed in response to TCR-signalling causing a
positive feedback loop, with T-bet increasing IFN-c, cytotoxicity
and IL-12 receptor expression [32]. In line with this, we found the
highest levels of T-bet in those CD8 T cells recovering maximal
cytokine productivity following IL-12 stimulation. In support of a
role for T-bet in the function of exhausted T cells, it has recently
been implicated in supporting effector cytokine production and
down-regulation of the co-inhibitory receptor PD-1 in chronic
Figure 3. Influence of IL-12 on IFN-c production by HBV and CMV-specific CD8 T cells. a) HBV- and CMV-specific CD8 T cells were detected
by HLA-A2/peptide dextramer staining and IFN-c production by the gated dextramer-positive cells was determined by intracellular FACS. FACS plots
gated on live CD192 CD3+ CD8+ T cells for HBV and CMV responses from 2 representative patients and summary data of the proportion of dextramer-
staining CD8 able to produce IFN-c are shown. b) Influence of IL-12 on IFN-c production by HBV dextramer+ T cells stimulated with corresponding
peptides. Representative FACS plot showing IFN-c production by gated dextramer+ T cells in the presence or absence of IL-12 and c) summary data
for each patient according to HBV viral load (log10IU/ml). ALT (IU/L) and patient identifier (P. ID) are shown; samples from patients with HBeAg+ CHB
are in bold (left) and combined for whole cohort (right); abbreviations: n.a. information not available, BLQ below limit of quantification. d) IFN-c
production by T cells gated on the CMV NLV-dextramer+ fraction in the presence or absence of IL-12, representative FACS stain and e) frequency of
IFN-c+ CMV NLVP-dextramer+ T cells from all individuals tested are shown (derived from healthy controls and CHB patients as denoted).
doi:10.1371/journal.ppat.1003208.g003
Figure 4. IL-12 promotes polyfunctional responses by HBV-specific T cells. a) Representative FACS plot showing IFN-c and TNF-a
production after restimulation of CD8 T cells with HBV-derived peptides. The summary data show the percentage of IFN-c/TNF-a double positive CD8
T cells out of all those producing either cytokine. b) Frequency of CD107a and c) IL-2 positive CD8 T cells upon restimulation with HBV-derived
peptide, cells were cultured in the presence or absence of IL-12. d) Expression levels of the pro-apoptotic molecule Bim in HBV-specific (IFN-c+) CD8 T
cells after culture in the presence or absence of IL-12; mean fluorescence intensity (MFI) is shown. All experiments were analysed after 10 day culture.
doi:10.1371/journal.ppat.1003208.g004
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Figure 5. Influence of IL-12 on PD-1 expression in HBV- and CMV-specific T cells. a) Frequency of PD-1+ HBV- or CMV-specific T cells
(defined as CD8+ IFN-c+) and (b) PD-1 expression levels as measured by MFI after short term culture in the presence or absence of IL-12, example
FACS plots and summary data are gated on CD8+ IFN-c+ T cells (n = 16 for overnight HBV, n = 27 for HBV- and n= 9 for CMV-specific 10 days). c) PD-1
MFI was compared on IFN-c+ CD8+ T cells after stimulation with HBV-derived peptide in the presence or absence of IL-12. Samples were then divided
according to whether PD-1 MFI decreased or not upon IL-12 stimulation. The graph shows the change in the frequency of IFN-c producing cells upon
IL-12 addition compared to peptide stimulation alone. d) PBMC were cultured with HBV derived peptides in the presence of IL-12; IFN-c positive cells
were divided into T-bet positive and negative cells according to an isotype staining control performed on IL-12 treated cells. PD-1 expression (mean
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LCMV infection in mice [23]. We found that IL-12 stimulation of
HBV-specific CD8 T cells resulted in the expansion of a
population with significantly lower levels of PD-1, correlating
with their recovery of function. However, PD-1 expression by IL-
12-stimulated HBV-specific CD8 T cells remained elevated
compared to levels on CMV-specific CD8 T cells and the addition
of PD-L1 blockade was able to further optimise the rescue of
antiviral responses. Prolonged exposure to IL-12 has recently been
suggested to upregulate the Tim-3 pathway in non-Hodgkin
lymphoma [33], lending further support to the strategy of
combining IL-12 with co-inhibitory pathway blockade for
maximal effect.
IL-12 has previously been found to activate sustained IFN-c
production by murine memory T cells without the need for
antigen recognition [2,4] analogous to the responses we saw by
global CD8 T cells and CMV-specific memory responses upon
stimulation with IL-12 in the absence of peptide. Although T cells
specific for the well-described HBV epitopes we focused on could
not be triggered to increase IFN-c by IL-12 alone, we cannot
exclude the possibility that CD8 T cells specific for other
subdominant HBV epitopes, which may constitute less exhausted
responses, could contribute to the bystander production. Recent
work suggests that IFN-c production by bystander CD8 T cells
may contribute to viral clearance in acute infections [34]; boosting
such bystander responses in CHB could potentially aid viral
control. Additionally the Th1 type CD4 response stimulated by
IL-12 may provide CD4 help in a non-antigen specific manner to
support HBV-specific CD8 T cells. In contrast to HBV-specific T
cells, IL-12 could not increase IFN-c production by CMV-specific
T cells once they had recognised their cognate antigen. This
suggests there are different requirements in the activation of
exhausted versus senescent T cells, respectively, strengthening the
notion that these two processes are independently regulated [22].
In summary, our data suggest that exhausted T cells may no
longer be amenable to activation by pro-inflammatory cytokines
alone but benefit from stimulation with IL-12 together with
cognate peptide. IL-12-treated T cells exhibited lower levels of
Bim and PD-1, both of which play a critical role in curtailing
responses that have been primed in the liver [11,24,35,36]. IL-12
was able to increase cytolytic and non-cytolytic responses and
enhance their multispecificity, even recovering responses directed
against epitopes from the HBV envelope antigen that cannot be
rescued by blockade of the PD-1 pathway [14]. Whereas blockade
of the PD-1 [14] or CTLA-4 [13] co-inhibitory pathways rescued
HBV-specific CD8 T cells in a proportion of patients, the addition
of IL-12 enhanced the functionality of responses in significantly
more patients, even those with extremely high viral loads. Patients
who had HBV viraemia well-suppressed on antivirals were still
responsive to IL-12 stimulation in vitro, suggesting that this may
form a rational addition to a therapeutic vaccine in this setting.
Such an approach has been used in macaque SIV infection, where
the addition of IL-12 to an SIV DNA vaccine boosted effector
memory CD8 T cells able to co-produce IFN-c/TNF-a [37].
Future studies will reveal whether our strategy of combining
antigenic stimulation, co-inhibitory blockade and IL-12 can
optimise the rescue of exhausted T cells in other persistent viral
infections.
Materials and Methods
Patients and controls
Ethics statement: This study was approved by the local ethical
board of the Royal Free Hospital and Camden Primary Care and
written informed consent was obtained from all participants. A
total of 98 patients with CHB and 4 healthy volunteers
participated in the study. All participants were HCV and HIV
sero-negative. All patients were treatment naı¨ve at the time of the
study unless otherwise specified. CHB patients were stratified by
eAg status, HBV DNA levels (determined by real-time PCR) and
HBsAg titre (quantified with the Architect assay, Abbot Diagnos-
tic). HLA-A2 status was determined by specific antibody (AbD
Serotec).
Over night and short-term cell culture and stimulation
PBMC were isolated by Ficoll-Hypaque density gradient
centrifugation and either analysed directly or cryopreserved. To
examine the effect of IL-12 and IFN-a on virus-specific T cells,
PBMCs from patients or CMV+ healthy controls were cultured for
10 days before analysis. Briefly, At the start of the culture PBMCs
from HLA A2+ donors were stimulated with 1 mM HBV-derived
HLA-A2 restricted peptides (core FLPSDFFPSV, envelope
FLLTRILTI, WLSLLVPFV, LLVPFVQWFV, GLSPTVWLSV,
polymerase GLSRYVARL, KLHLYSHPI) (Proimmune) or if
derived from HLA-A2 negative donors with 1 mM OLP spanning
the whole HBV core protein, sequence correlating to HBV
genotype D (AYW) (JPT Peptide Technologies). OLP spanning
only HBV core were used to minimise inter-genotypic sequence
variation. Control responses to CMV from HLA-A2+ individuals
were measured using 1 mM NLVPMVATV (Proimmune). At the
same time point rhIL-12 (Miltenyi Biotech) was added at 10 ng/ml,
rhIFN-a (PBL Biomedical Laboratories) at 1000 IU/ml and
function blocking anti-PD-L1, anti-PD-L2 and control IgG
(eBiosciences) were used at 5 mg/ml. All cultures were supplement-
ed with 20 U/ml rhIL-2 (Miltenyi Biotech) at day 0 and 4. PBMCs
were restimulated on day 9 by re-adding peptide at the original
concentration and culturing over night in the presence of 1 mg/ml
Brefeldin A (Sigma-Aldrich). Virus-specific responses were identi-
fied by IFN-c production. For detection of CD107a 1 mg/ml
Monensin (Sigma-Aldrich) was also added during restimulation. To
assess ex vivo IFN-c+ responses, PBMC were stimulated overnight
with 5 mM of HBV peptides either representing HLA-A2 restricted
epitopes or spanning HBV core (as described above). IL-12 was
used at 10 ng/ml. Cultures were not supplemented with IL-2.
Brefeldin A was added 1 h after addition of peptide and IL-12.
Intrahepatic lymphocyte isolation and functional assay
Liver sections from biopsies were homogenised and filtered.
PBMC and liver cell suspensions from the same patient were
stimulated over night with core OLP in the presence or absence of
IL-12, in the presence of Brefeldin A. Virus-specific responses were
identified by IFN-c production as described for PBMC above.
Flow cytometric analysis
9 or 10 colour flow cytometry was used for all experiments.
PBMCs were stained for surface markers CD3, CD8 (eBioscience)
and PD-1 (Biolegend). Dead cells were always excluded using live/
fluorescence intensity) was compared in both groups. e) IFN-c positive T cells were divided into IFN-c low and IFN-c high positive cells, defined by
background IFN-c production by CD8+ T cells in unstimulated samples. T-bet expression in IFN-c low and high producing T cells was compared in
samples tested after stimulation with HBV peptide and IL-12. f) Frequency of T-bet positivity in T cells producing either IFN-c or TNF-a alone or co-
producing both cytokines.
doi:10.1371/journal.ppat.1003208.g005
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Figure 6. Blocking PD-1 signalling in combination with IL-12 enhances virus-specific responses. a) % IFN-c+CD8+ upon peptide
stimulation +/2PD-L blockade and IL-12 stimulation for all patients tested, presented for each patient in order of increasing viral load (VL) (log10IU/
ml), ALT indicated in IU/L and eAg+ samples are shown in bold. Patient identifiers start with A for HLA-A2+ and with B for HLA-A22 donors. b)
Representative FACS plots showing IFN-c production upon restimulation with HBV derived peptides after blockade of PD-L1 and PD-L2 by a specific
antibody, IL-12 stimulation or the combination and graph showing summary data for all patients. c) Functional recovery of HLA-A2/HBV dextramer+ T
cells upon PD-L1/2 blockade, IL-12 stimulation or the combination. (VL (log10IU/ml), ALT (IU/L), patient ID (P. ID), n.a. = not available, BLQ=below limit
of quantification. All data were acquired after 10 days culture and peptide restimulation overnight.
doi:10.1371/journal.ppat.1003208.g006
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dead fixable dye staining kit (Invitrogen). Cells were then fixed and
permeabilized and intracellular molecules were detected using anti
IFN-c, TNF-a, CD107a (BD Biosciences), IL-2, Tbet (eBioscience)
and Bim (Alexis). All samples were acquired on a BD LSRII or BD
Fortessa. All analysis was performed using Flowjo (Tree Star).
Staining for multimer+ T cells and intracellular cytokine
production
HBV and CMV-specific HLA-A2 dextramers (Immudex) were
titrated to determine optimal staining concentrations. For detection of
HBV-specific T cells we used core FLPSDFFPSV, envelope
FLLTRILTI, WLSLLVPFV, GLSPTVWLSV, polymerase GLSRY-
VARL, KLHLYSHPI. CMV-specific dextramers were loaded with
NLVPMVATV; as a control for unspecific staining, dextramer loaded
with irrelevant peptide was used (Figure S3b). Briefly, cells were stained
with dextramers, washed and stimulated with peptide for 1 h before
the addition of Brefeldin A. After 5 h incubation cells were stained with
the surface marker antibodies, live/dead staining and anti-CD19 (BD
Biosciences) to exclude dead cells and non-specific binding, respec-
tively. Intracellular cytokines were detected as described.
Statistical analysis
Statistical analyses were performed using the non-parametric
Mann-Whitney or Wilcoxon matched pairs test as appropriate and
significant differences marked on figures (* = p,0.05;
** = p,0.005; ***= p,0.0005).
Supporting Information
Figure S1 IL-12 enhances IFN-c production in IHL
overnight. PBMC and IHL derived from the same patient were
stimulated with core OLP over night in presence or absence of IL-
12. IFN-c production was assessed by intracellular cytokine staining.
a) Example FACS plot comparing IFN-c production by CD8T cells
derived from PBMC and IHL and b) summary data of all patients
tested. VL (IU/ml) is shown as log10, all patients were eAg negative.
(EPS)
Figure S2 Effect of IL-12 on IFN-c production by HBV-
stimulated CD8 is maintained on antiviral treatment.
PBMC from patients before and after starting antiviral treatment
were stimulated with HBV derived peptides with or without IL-12
for 10 days, before restimulation overnight. Each graph compares
the IFN-c responses of a single patient before and on treatment.
(EPS)
Figure S3 The gating strategy for detection of virus-
specific T cells by dextramer staining. a) The consecutive
gating strategy is shown. Cells were gated for lymphocytes
according to forward and side scatter properties, large cells were
included to encompass activated and dividing T cells. Dead cells
staining positive with a live/dead staining kit were excluded. Cells
were further gated on the CD3+ but CD19 negative population,
since CD19+ cells can cause non-specific binding. b) CD8+ T cells
were stained with a combination of HLA-A2 dextramers loaded
with peptides derived from HBV-core, envelope and polymerase
(see methods). As a gating control cells were also stained with an
HLA-A2 dextramer loaded with an irrelevant peptide.
(EPS)
Figure S4 The frequency of HBV-dextramer positive T
cells is not increased by IL-12 treatment. Frequency of
HBV dextramer+ T cells in 10 day cultures stimulated with HLA-
A2 restricted HBV peptides with or without the addition of IL-12.
(EPS)
Figure S5 IL-12 boosts CD8 T cell responses to epitopes
derived from HBV-core, -envelope and -polymerase.
PBMC were stimulated with either, core, envelope or polymerase
derived HLA-A2 restricted peptides in the presence or absence of IL-
12. CD8 T cells were stained with the corresponding HBV-specific
dextramers on day 10 and subsequently restimulated with peptide for
5 hrs. IFN-c production was detected by intracellular staining and
flowcytometric analysis. A representative FACS plot a) and summary
data b) for the three patients tested are shown. n.d. signifies no or
insufficient dextramer+ cells for analysis could be detected.
(EPS)
Figure S6 HBV-specific T cells from resolved patients
exhibit robust anti-HBV responses that are not signifi-
cantly boosted by IL-12. PBMCs from resolved patients were
stimulated with HBV-derived peptide in the presence or absence
of IL-12 and cultured for 10 days. Peptide-specific CD8 T cells
were visualised using HBV-specific dextramers and cells subse-
quently restimulated with the respective peptides in the presence of
brefeldin A. Dextramer+ IFN-c+ CD8 T cells were quantified by
flow cytometry, a) representative FACS plot and b) summary data.
(EPS)
Figure S7 IL-12 mediated decrease of PD-1 correlates
with increased CD8 IFN-c response. PBMC were stimulated
in short term cultures either with HBV peptide alone or with HBV
peptide in combination with IL-12. The fold change of PD-1 MFI
on IFN-c+ CD8 T cells between the two settings is shown, positive
values show fold increase, negative values fold decrease, (black
bars), and the difference in the % IFN-c response (%IFN-c
(HBV+IL-12) - % IFN-c (HBV)) is shown (grey bars). Viral load
(log10 IU/ml), ALT (IU/L) and patient ID (P. ID).
(EPS)
Table S1 Table showing patient data for Figure S2.
(PDF)
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